遠大醫藥(00512.HK)創新放射性藥物海外三期研究達臨床終點
遠大醫藥(00512.HK)公布,集團在放射性核素偶聯藥物領域的重要戰略合作夥伴Telix宣布了用於診斷透明細胞腎細胞癌的藥物TLX250-CDx的海外三期臨床研究的積極頂線數據。
根據試驗結果顯示,對於通過目前臨床常用診斷方法電子掃瞄(CT)或磁力共振(MRI)提示存在腎臟腫塊但無法判斷是否為透明細胞腎細胞癌的患者,TLX250-CDx正電子發射斷層成像(PET)在診斷透明細胞腎細胞癌的敏感性和特異性上分別達到86%和87%,遠超過美國食品和藥物管理局要求的預設閾值,陽性預測值可達93%,成功達到了主要臨床終點和次要臨床終點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.